İskemik İnme Hastalarında Serum Asprosin Ve Adiponektin Düzeylerinin Araştırılması

Yıl 2024, Cilt: 21 Sayı: 3, 540 - 546, 27.12.2024

Fatma Şimşek , Esra Eğilmez

https://doi.org/10.35440/hutfd.1564881

Öz

Amaç: İskemik inmeli hastalarda akut fazda asprosin ve adiponektin düzeylerinin ve asprosin ve adiponektinin birbirleriyle ve kısa dönem prognozla olan ilişkisinin araştırılması amaçlanmıştır.
Materyal ve metod: Mart 2022-Haziran 2022 tarihleri arasında akut iskemik inme tanısı ile ardışık olarak gelen hastalar ve cinsiyet-yaş eşleştirilmiş kontrol grubu çalışmaya alındı. Her iki grupta da serum asprosin, adiponektin düzeyi ve rutin testler incelendi.
Bulgular: İnme hastalarında serum asprosin düzeyi kontrol grubuna göre önemli ölçüde düşüktü (p=0,012). Serum adiponektin düzeyi kontrol grubuna göre düşük fakat istatistiksel olarak anlamlı değildi (p=0,126). Serum asprosin düzeyi ile Ulusal Sağlık Enstitüsü İnme Skoru arasında negatif yönde bir korelasyon vardı (r=-0,423, p=0,004). Serum adiponektin düzeyi ile Ulusal Sağlık Enstitü-sü İnme Skoru arasında anlamlı bir korelasyon yoktu (r=-0,234, p=0,122). Serum asprosin ve adi-ponektin düzeyleri arasında pozitif bir korelasyon vardı (r=0,667, p<0,001). Akut dönemdeki asprosin ve adiponektin düzeyi ile ikinci aydaki sakatlık düzeyi arasında bir ilişki yoktu (r=-0,267, p=0,077; r=-0,068, p=0,658).
Sonuç: Asprosin düzeyindeki düşme artmış iskemik inme riski ve akut inme şiddeti ile ilişkilidir.

Anahtar Kelimeler

asprosin, adiponektin, akut iskemik inme

Etik Beyan

Atatürk Üniversitesi tıp fakültesi klinik araştırmalar etik kurulu tarafından onaylandı (07/56/04.11.2021).

Destekleyen Kurum

Atatürk Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi

Proje Numarası

TAB-2022-10383

Teşekkür

Çalışmamız Atatürk Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi tarafından desteklenmiştir. Desteklerinden dolayı teşekkür ederiz

The Assessment of the Serum Asprosin and Adiponectin Levels in Ischemic Stro-ke Patients

Öz

Background: The aim of this study was to investigate asprosin and adiponectin levels in the acute phase in patients with ischemic stroke and to investigate the relationship between asprosin and adiponectin and short-term prognosis.
Materials and Methods: The study sample consisted of consecutive patients who were admitted with the diagnosis of acute ischemic stroke between March 2022 and June 2022 and control sub-jects with gender and age characteristics that match the patients. Serum asprosin and adiponectin levels were assessed and routine tests were carried out in both patient and control groups.
Results: Serum asprosin level was significantly lower in the patient group than in the control group (p=0.012). Serum adiponectin level was lower than the control group but it was not statistically significant (p=0.126). There was a negative correlation between National Institutes of Health Stroke Score and serum asprosin level (r=-0.423, p=0.004), but not between serum adiponectin level (r=-0.234, p=0.122). There was a positive correlation between serum asprosin and adiponec-tin levels (r=0.667, p<0.001). There was no relationship between asprosin and adiponectin levels in the acute period and disability level in the second month (r=-0,267, p=0,077; r=-0,068, p=0,658).
Conclusions: A decrease in asprosin levels is associated with an increased risk of ischemic stroke and acute stroke severity.

Keywords: Asprosin, Adiponectin, Acute ischemic stroke

Anahtar Kelimeler

Asprosin, Adiponectin, Acute ischemic stroke

Proje Numarası

TAB-2022-10383

Kaynakça

• 1. Parr E, Ferdinand P, Roffe C. Management of Acute Stroke in the Older Person. Geriatrics. 2017; 2(3):27.
• 2. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell Biology of Ischemia/Reperfusion Injury. Int Rev Cell Mol Biol. 2012; 298:229–317.
• 3. Thundyil J, Pavlovski D, Sobey CG, Arumugam T V. Adiponec-tin receptor signalling in the brain. Br J Pharmacol. 2012; 165(2):313.
• 4. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hy-perinsulinemia. J Clin Endocrinol Metab. 2001; 86(5):1930–5.
• 5. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361(9353):226–8.
• 6. Miao J, Shen LH, Tang YH, Wang YT, Tao MX, Jin KL, et al. Overexpression of Adiponectin Improves Neurobehavioral Outcomes After Focal Cerebral Ischemia in Aged Mice. CNS Neurosci Ther. 2013; 19(12):969.
• 7. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, et al. Role of Adiponectin in Preventing Vascular Stenosis. J Biol Chem. 2002; 277(40):37487–91.
• 8. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, et al. Adiponectin Prevents Cerebral Ischemic Injury Thro-ugh Endothelial Nitric Oxide Synthase–Dependent Mecha-nisms. Circulation. 2008; 117(2):216–23.
• 9. Chen S, Wang X, Qiu CM, Hou JN, Wei XY, Xiang CX, et al. [Study of the Role and Mechanism of Asprosin/Spartin Pathway in Cardiac Microvascular Endothelial Injury Induced by Diabete Mellitus]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2019; 50(6):827–34.
• 10. Adams HP, Bendixen BH, Kappelle ; L Jaap, Biller J, Love BB, David ;, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TO-AST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35–41.
• 11. Brott T, Marler JR, Olinger CP, Adams HP, Tomsick T, Barsan WG, et al. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke. 1989; 20(7):871–5.
• 12. Goldstein BJ, Scalia R. Adiponectin: A Novel Adipokine Lin-king Adipocytes and Vascular Function. J Clin Endocrinol Me-tab. 2004; 89(6):2563–8.
• 13. Zhang Y-Q, Zhang Y-W, Dai J-L, Li C, Wang W-Q, Zhang H-F, et al. Serum CTRP9 and high-molecular weight adiponectin are associated with ischemic stroke. BMC Neurol. 2022; 22(1):429.
• 14. Liu H, Wu X, Luo J, Zhao L, Li X, Guo H, et al. Adiponectin peptide alleviates oxidative stress and NLRP3 inflammasome activation after cerebral ischemia-reperfusion injury by re-gulating AMPK/GSK-3β. Exp Neurol. 2020; 329:113302.
• 15. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE, McGinn AP, et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: Results from the women’s health initiative. Stroke. 2011; 42(7):1813–20.
• 16. Khalili P, Flyvbjerg A, Frystyk J, Lundin F, Jendle J, Engström G, et al. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term fol-low-up study. Diabetes Metab. 2010; 36(2):137–43.
• 17. Arregui M, Buijsse B, Fritsche A, Giuseppe R Di, Schulze MB, Westphal S, et al. Adiponectin and risk of stroke : Prospecti-ve study and meta-analysis. Stroke. 2014; 45(1):10–7.
• 18. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Adiposity, adipokines, and risk of incident stroke in older men. Stroke. 2013; 44(1):3–8.
• 19. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P, Sowers MR, Rajpathak SN, Allison MA, et al. High-molecular-weight adiponectin and incident ischemic stroke in postme-nopausal women: A women’s health initiative study. Stroke. 2010; 41(7):1376–81.
• 20. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardio-vascular health: an update. Br J Pharmacol. 2012; 165(3):574–90.
• 21. Kuwashiro T, Ago T, Kamouchi M, Matsuo R, Hata J, Kuroda J, et al. Significance of plasma adiponectin for diagnosis, ne-urological severity and functional outcome in ischemic stro-ke — Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism. 2014; 63(9):1093–103.
• 22. Lasek-Bal A, Jedrzejowska-Szypulka H, Student S, Warsz-Wianecka A, Zareba K, Puz P, et al. The importance of selec-ted markers of inflammation and blood-brain barrier dama-ge for short-term ischemic stroke prognosis. J Physiol Phar-macol. 2019; 70(2).
• 23. Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, et al. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine (Baltimore). 2020; 99(12).
• 24. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, et al. Impaired insulin sensitivity among nondi-abetic patients with a recent TIA or ischemic stroke. Neuro-logy. 2003; 60(9):1447–51.
• 25. Jing J, Pan Y, Zhao X, Zheng H, Jia Q, Mi D, et al. Insulin Resis-tance and Prognosis of Nondiabetic Patients with Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regula-tion in Patients with Acute Stroke Across China). Stroke. 2017; 48(4):887–93.
• 26. Wang R, Hu W. Asprosin promotes β-cell apoptosis by inhibi-ting the autophagy of β-cell via AMPK-mTOR pathway. J Cell Physiol. 2021; 236(1):215–21.
• 27. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016; 165(3):566–79.
• 28. Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, et al. Aspro-sin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019; 234(11):20888–99.
• 29. Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, et al. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019; 30(2):319-328.e8.
• 30. Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. Mediators Inflamm. 2018;2018(1):7375294.
• 31. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyce-ride. Clin Chim Acta. 2019; 489:183–8.
• 32. Güler S, Güler Ş. The evaluation of serum asprosin concent-ration in minor ischemic stroke. PONTE Int Sci Res J. 2021; 77(6).
• 33. Lei S-F, Li bin-G, Zhou J, Wang D-K, Luo Z. Serum asprosin levels in patients with acute ischemic stroke. Neurol Asia. 2023;28(1):81–8.
• 34. Feng J, Yang Y, Yang Y, Pei H. GW29-e0080 The protective role of Asprosin against diabetes in cardiomyocytes. J Am Coll Cardiol. 2018 Oct 16; 72(16):C2.
• 35. Naiemian S, Naeemipour M, Zarei M, Lari Najafi M, Gohari A, Behroozikhah MR, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020; 12(1):1–8.
• 36. Kocaman N, Kuloğlu T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its chan-ges in a streptozotocin-induced diabetes mellitus model. Tissue Cell. 2020; 66:101397.